PT2582683T - Tratamento da gota e de hiperuricemia - Google Patents

Tratamento da gota e de hiperuricemia

Info

Publication number
PT2582683T
PT2582683T PT117963249T PT11796324T PT2582683T PT 2582683 T PT2582683 T PT 2582683T PT 117963249 T PT117963249 T PT 117963249T PT 11796324 T PT11796324 T PT 11796324T PT 2582683 T PT2582683 T PT 2582683T
Authority
PT
Portugal
Prior art keywords
hyperuricemia
drop
treatment
Prior art date
Application number
PT117963249T
Other languages
English (en)
Portuguese (pt)
Inventor
Girardet Jean-Luc
Miner Jeffrey
D Quart Barry
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2582683(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of PT2582683T publication Critical patent/PT2582683T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117963249T 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia PT2582683T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24

Publications (1)

Publication Number Publication Date
PT2582683T true PT2582683T (pt) 2018-05-25

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117963249T PT2582683T (pt) 2010-06-15 2011-06-14 Tratamento da gota e de hiperuricemia

Country Status (19)

Country Link
US (3) US9216179B2 (cg-RX-API-DMAC7.html)
EP (1) EP2582683B1 (cg-RX-API-DMAC7.html)
JP (1) JP5964821B2 (cg-RX-API-DMAC7.html)
CA (1) CA2802407C (cg-RX-API-DMAC7.html)
CY (1) CY1120473T1 (cg-RX-API-DMAC7.html)
DK (1) DK2582683T3 (cg-RX-API-DMAC7.html)
ES (1) ES2670700T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180780T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038265T2 (cg-RX-API-DMAC7.html)
LT (1) LT2582683T (cg-RX-API-DMAC7.html)
NO (1) NO2019008I1 (cg-RX-API-DMAC7.html)
PL (1) PL2582683T3 (cg-RX-API-DMAC7.html)
PT (1) PT2582683T (cg-RX-API-DMAC7.html)
RS (1) RS57275B1 (cg-RX-API-DMAC7.html)
SI (1) SI2582683T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800266T1 (cg-RX-API-DMAC7.html)
TR (1) TR201806828T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011159732A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300055B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
EP3501520A1 (en) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063788A1 (ja) 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
DK2135608T3 (da) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
CN101646440A (zh) 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2736117C (en) 2008-09-04 2013-11-19 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
US20130296345A1 (en) * 2010-10-15 2013-11-07 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
LT2658846T (lt) 2010-12-30 2017-02-27 Ardea Biosciences, Inc. 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acto rūgšties polimorfinės formos ir jų panaudojimas
ES2633762T3 (es) 2011-05-24 2017-09-25 Ardea Biosciences, Inc. Hipertensión e hiperuricemia

Also Published As

Publication number Publication date
US9216179B2 (en) 2015-12-22
US20160143889A1 (en) 2016-05-26
US20190015392A1 (en) 2019-01-17
DK2582683T3 (en) 2018-06-06
HUE038265T2 (hu) 2018-10-29
RS57275B1 (sr) 2018-08-31
SMT201800266T1 (it) 2018-07-17
EP2582683B1 (en) 2018-03-21
ZA201300055B (en) 2018-05-30
CA2802407A1 (en) 2011-12-22
PL2582683T3 (pl) 2018-08-31
ES2670700T3 (es) 2018-05-31
WO2011159732A1 (en) 2011-12-22
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
NO2019008I1 (no) 2019-02-19
JP2013528650A (ja) 2013-07-11
SI2582683T1 (en) 2018-07-31
CA2802407C (en) 2018-01-23
EP2582683A1 (en) 2013-04-24
EP2582683A4 (en) 2014-04-30
HRP20180780T1 (hr) 2018-07-13
CY1120473T1 (el) 2019-07-10
TR201806828T4 (tr) 2018-06-21
JP5964821B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
PT2582683T (pt) Tratamento da gota e de hiperuricemia
HUS1900001I1 (hu) Transztiretin expressziójának módosítása
BR112013002845A2 (pt) combinação de susbtâncias ativas
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
PT2616087T (pt) Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
EP2534248A4 (en) Selective reduction of allelic variants
EP2534262A4 (en) SELECTIVE REDUCTION OF ALL-VARIANTS
HUE036439T2 (hu) Antimikrobiális készítmények és azok alkalmazási módszerei
BR112013009496A2 (pt) artigos absorventes e métodos de fabricação dos mesmos
EP2785404A4 (en) CATHETER DEVICES AND METHOD THEREFOR
BR112012017441A2 (pt) compostos e métodos
BR112012026334A2 (pt) aparelho de cateter e introdutor de cateter
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
EP2549986A4 (en) MACROPHONE LEAVE TO MULTIPLE OBJECTIVES
EP2489334A4 (en) MEDICAL STENT
PL2523678T3 (pl) Antagoniści Wnt i sposoby leczenia
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
BR112014006291A2 (pt) composição e utilização da composição
BR112014031086A2 (pt) tratamento e prevenção de doenças cardiovasculares e trombose
BR112013002544A2 (pt) seção de armario e armario
BR112013009579A2 (pt) método e comprimido
SMT201600059B (it) Trattamento di infezioni da streptococco
HRP20181436T1 (hr) Postupak za primjenu nanočestica
EP2611440A4 (en) TREATMENT OF COCAINE
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER